These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26490332)

  • 1. Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nóbrega C; Carmo-Silva S; Albuquerque D; Vasconcelos-Ferreira A; Vijayakumar UG; Mendonça L; Hirai H; de Almeida LP
    Brain; 2015 Dec; 138(Pt 12):3537-54. PubMed ID: 26490332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.
    Simões AT; Gonçalves N; Koeppen A; Déglon N; Kügler S; Duarte CB; Pereira de Almeida L
    Brain; 2012 Aug; 135(Pt 8):2428-39. PubMed ID: 22843411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
    Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
    Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
    Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
    Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
    Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
    Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
    Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
    Dantuma NP; Herzog LK
    Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
    Gonçalves N; Simões AT; Cunha RA; de Almeida LP
    Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
    Duarte-Neves J; Gonçalves N; Cunha-Santos J; Simões AT; den Dunnen WF; Hirai H; Kügler S; Cavadas C; Pereira de Almeida L
    Hum Mol Genet; 2015 Oct; 24(19):5451-63. PubMed ID: 26220979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado-Joseph disease models.
    Mendonça LS; Nóbrega C; Tavino S; Brinkhaus M; Matos C; Tomé S; Moreira R; Henriques D; Kaspar BK; Pereira de Almeida L
    Hum Mol Genet; 2019 Nov; 28(22):3691-3703. PubMed ID: 31127937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
    Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
    Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Machado-Joseph disease-associated expanded form of ataxin-3: Overexpression, purification, and preliminary biophysical and structural characterization.
    Contessotto MGG; Rosselli-Murai LK; Garcia MCC; Oliveira CLP; Torriani IL; Lopes-Cendes I; Murai MJ
    Protein Expr Purif; 2018 Dec; 152():40-45. PubMed ID: 30036587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.
    Lin GY; Ma CY; Kuo LC; Hsieh BY; Wang H; Liu CS; Hsieh M
    Metab Brain Dis; 2022 Aug; 37(6):2103-2120. PubMed ID: 35488942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease.
    Simões AT; Gonçalves N; Nobre RJ; Duarte CB; Pereira de Almeida L
    Hum Mol Genet; 2014 Sep; 23(18):4932-44. PubMed ID: 24817574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
    Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
    Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
    Hübener J; Riess O
    Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
    Costa MDC; Ashraf NS; Fischer S; Yang Y; Schapka E; Joshi G; McQuade TJ; Dharia RM; Dulchavsky M; Ouyang M; Cook D; Sun D; Larsen MJ; Gestwicki JE; Todi SV; Ivanova MI; Paulson HL
    Brain; 2016 Nov; 139(11):2891-2908. PubMed ID: 27645800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
    Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L
    Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3.
    Weber JJ; Golla M; Guaitoli G; Wanichawan P; Hayer SN; Hauser S; Krahl AC; Nagel M; Samer S; Aronica E; Carlson CR; Schöls L; Riess O; Gloeckner CJ; Nguyen HP; Hübener-Schmid J
    Brain; 2017 May; 140(5):1280-1299. PubMed ID: 28334907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.